MedTrace Logo

A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

NCT03044249 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2021-04-01

Study results available
· View outcomes & findings →

Summary

A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

Conditions

Interventions

DRUG

MP-101

Capsules

DRUG

Placebo

Capsules

Sponsors & Collaborators

  • Mediti Pharma Inc.

    lead OTHER

Principal Investigators

  • Mediti Pharma · Mediti Pharma Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-04
Primary Completion
2020-01-30
Completion
2020-01-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03044249 on ClinicalTrials.gov